Enzymatic DNA synthesis company Ansa Biotechnologies hopes to win a slice of the nucleic acid synthesis market with ultra-long DNA products that it believes are hard to obtain with traditional phosphoramidite-based chemical synthesis.
When Jason T. Gammack talks about DNA synthesis, he does not start with base chemistry or instrument design. He starts with broken promises. For decades, synthetic biology teams have designed pathways in hours, then waited weeks or months for gene fragments that arrived late, arrived wrong, or never arrived at all. Read the full article from SynBioBeta.
Ansa plans to use some of the funding to expand its facility in Emeryville, CA. The company will install an upgraded version of its technology which will make its DNA manufacturing more efficient. New manufacturing platforms will also be added at the Emeryville site to expand production capacity. Read the full story.
An article in Nature features Ansa’s Chief Scientific Officer and co-founder Dan Lin-Arlow discussing the unique capabilities of enzymatic DNA synthesis. Read the full story here.
Read this editorial in Technology Networks by Ansa CSO and co-founder Dan Lin-Arlow to learn about the factors you should consider if you are looking to switch to enzymatic synthesis.
The importance of Ansa’s technology to enable synthesis of complex DNA for advanced research is featured in this editorial from Biocompare.
Ansa Biotechnologies’ DNA synthesis technology and first product launch are featured in this story from SynbioBeta.
Ansa’s enzymatic DNA synthesis is featured in Genetic Engineering & Biotechnology News.Read the article
The Scientist article highlighting the need to move beyond chemical DNA synthesis in order to continue pushing science further. Featuring Ansa co-founder and Chief Science Officer, Dan Lin-Arlow.
Nature Biotechnology news feature on the promises and implications of new DNA synthesis technologies, featuring comments from Ansa Biotechnologies’ Dan Lin-Arlow.